论文部分内容阅读
目的探讨胃癌前病变(PLGC)Bcl-2、P~(53)基因蛋白的表达及胶体果胶铋胶囊的治疗机制。方法选取临床胃镜诊断胃癌前病变病例共120例,随机分为两组,分别用胶体果胶铋胶囊与维酶素治疗,观察对病变粘膜组织中Bcl-2、P~(53)基因蛋白水平的影响。结果治疗组能明显阻断化学致癌物对粘膜的炎症损伤,改善癌前病变组织粘膜不典型增生程度。同时应用胶体果胶铋胶囊治疗后Bcl-2、P~(53)基因蛋白阳性指数亦明显低于病理对照组(P<0.05)。结论胶体果胶铋胶囊通过降低PLGC患者病变组织增殖水平,诱导细胞正常凋亡,从而对胃癌前病变细胞的增殖有良好的阻断作用。
Objective To investigate the expression of Bcl-2, P53 gene in gastric precancerous lesions (PLGC) and the therapeutic mechanism of colloidal pectin bismuth capsules. Methods A total of 120 cases of gastric precancerous lesions diagnosed by clinical endoscopy were selected and divided into two groups at random. The rats were treated with bismuth gel capsules and vinorelbine respectively. The protein levels of Bcl-2 and p53 in the diseased mucosa tissues were observed. Impact. Results The treatment group could obviously block the inflammatory damage of chemical carcinogens to the mucosa and improve the mucosal atypical hyperplasia of precancerous lesions. At the same time, the positive index of Bcl-2 and P53 gene in colloidal pectin bismuth capsules was significantly lower than that in the pathological control group (P <0.05). Conclusion Colloidal pectin bismuth capsules can inhibit the proliferation of precancerous cells in gastric cancer by decreasing the proliferation of the lesion in PLGC patients and inducing the normal apoptosis of the cells.